Ostarine will be the closest SARM to currently being authorized in medication and is also presently in section II clinical trials. Like SARMs on the whole, MK-2866 targets androgen receptors on a selective basis and avoids building the kinds of hazardous side effects affiliated with substances like testosterone, human growth https://johnm382xjg9.blog-gold.com/profile